Vaccination with tumour-associated antigens (TAAs) has been reported to lead to expansion and accumulation of CD8+ CTLs within the tumour, resulting in enhancement of tumour regression.21, 22 Previously, we have reported that virus-like particles (VLP) derived from rabbit haemorrhagic virus (RHDV) can be used as a vaccine construct to deliver TAAs to elicit a proliferative response of antigen-specific T cells and subsequent elimination of target cells in vivo. The gene discussed is CD8A; the disease is neoplasm.